TransMedics Group (NASDAQ:TMDX) & Vivani Medical (NASDAQ:VANI) Financial Analysis

TransMedics Group (NASDAQ:TMDX) and Vivani Medical (NASDAQ:VANI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Profitability

This table compares TransMedics Group and Vivani Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TransMedics Group	-3.43%	7.95%	1.61%
Vivani Medical	N/A	-93.91%	-47.76%

Institutional and Insider Ownership

99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 6.8% of Vivani Medical shares are owned by institutional investors. 7.0% of TransMedics Group shares are owned by company insiders. Comparatively, 55.6% of Vivani Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for TransMedics Group and Vivani Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0	1	9	0	2.90
Vivani Medical	0	0	0	0	N/A

TransMedics Group presently has a consensus target price of $133.88, indicating a potential downside of 5.85%. Given TransMedics Group’s higher probable upside, equities analysts clearly believe TransMedics Group is more favorable than Vivani Medical.

Risk & Volatility

TransMedics Group has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500. Comparatively, Vivani Medical has a beta of 3.23, meaning that its share price is 223% more volatile than the S&P 500.

Valuation & Earnings

This table compares TransMedics Group and Vivani Medical’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$241.62 million	19.38	-$25.03 million	($0.34)	-418.21
Vivani Medical	N/A	N/A	-$25.65 million	($0.50)	-2.68

TransMedics Group has higher revenue and earnings than Vivani Medical. TransMedics Group is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks.

Summary

TransMedics Group beats Vivani Medical on 8 of the 12 factors compared between the two stocks.

About TransMedics Group

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

About Vivani Medical

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.